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Abstract. Polyethylene glycol (PEG) hydrogels are widely used in a variety of biomedical applications,
including matrices for controlled release of biomolecules and scaffolds for regenerative medicine. The
design, fabrication, and characterization of PEG hydrogels rely on the understanding of fundamental
gelation kinetics as well as the purpose of the application. This review article will focus on different
polymerization mechanisms of PEG-based hydrogels and the importance of these biocompatible
hydrogels in regenerative medicine applications. Furthermore, the design criteria that are important in
maintaining the availability and stability of the biomolecules as well as the mechanisms for loading of
biomolecules within PEG hydrogels will also be discussed. Finally, we overview and provide a
perspective on some of the emerging novel design and applications of PEG hydrogel systems, including
the spatiotemporal-controlled delivery of biomolecules, hybrid hydrogels, and PEG hydrogels designed
for controlled stem cell differentiation.
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INTRODUCTION
Multiple physical, chemical, and biological cues are
known to act cooperatively and/or synergistically to affect
cellular function during tissue regeneration in vitro and in
vivo (1). To design successful biomaterials for facilitating
tissue regeneration, one must thoughtfully consider the
interplay between the targeted cells/tissues and these envi-
ronmental cues. Important factors often include soluble
growth factors, cell–cell and cell–material interactions, and
mechanical properties of the microenvironment (1). Among
these, the delivery of bioactive molecules has been the subject
of intensive research, and the targeted molecules are diverse,
including low molecular weight drugs, nucleic acids, peptides,
and proteins, for the accelerated regeneration of tissues. With
respect to their role as delivery vehicles, hydrogels are a class
of materials with numerous advantages to simultaneously
encapsulate cells and biomolecules, and numerous gel sys-
tems allow one to intimately control the release character-
istics through systematic changes in the gel’s physical and
chemical structure (2). With respect to tailoring gel proper-
ties, those derived from synthetic polymers, such as poly
(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), poly(N-
isopropylacrylamide) (PNIPAAM), are particularly useful
and have been used in numerous regenerative medicine
applications (3). Of these, the non-ionic, hydrophilic PEG
gel systems are increasingly used and represent the focus of
this review.
Over the past few decades, poly(ethylene glycol) (PEG)
hydrogels have been extensively used as matrices for
controlling drug delivery, as well as cell delivery vehicles for
promoting tissue regeneration (4–7). The versatility of the
PEG macromer chemistry (8), together with its excellent
biocompatibility, has spurred the development of numerous
intelligently-designed hydrogel systems for regenerative med-
icine applications. Many of these studies have produced
encouraging pre-clinical and clinical results. In the context
of controlled delivery, properly designed PEG hydrogels play
an important role in directing cellular functions that are
important for survival, proliferation, secretory properties, and
even differentiation. The objectives and design principles for
this purpose are two-fold: to provide local and extended
release of the loaded therapeutics to augment the therapeutic
effect; and to decrease the adverse reactions and preserve the
bioactivity of the therapeutics. To achieve these goals, one
has to carefully consider several critical factors, including the
physiological environments of the target tissues, gelation and
molecule loading/release mechanisms, molecular character-
istics of the therapeutics to be delivered, as well as potential
interactions with the polymeric hydrogels.
PEG hydrogels provide a unique niche for cell encapsula-
tion, as they are highly biocompatible to the cells under proper
polymerization conditions (9). Through co-polymerization with
other macromolecules, multiple functional moieties are readily
introduced to suppress or promote cell survival and function.
For example, the integrin binding peptide Arg-Gly-Asp (or
RGD) is often introduced as a pendant functional group within
otherwise bio-inert PEG hydrogels to promote the survival of
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adherent-dependent cells, such as osteoblasts (10). While PEG
hydrogel environments are generally highly permissible and
allow for facile diffusion of nutrients, this property often
hinders the localized delivery and therapeutic efficacy of
soluble factors targeted to the encapsulated cells, as the inert
gel networks are equally permeable to the co-encapsulated
therapeutics. The means by which bioactive molecules are
presented to encapsulated cells within PEG hydrogel networks
(both temporally and spatially) is, therefore, a major challenge
in the design of hydrogel delivery systems and is currently a
subject of intense research.
As we entered into the proteomic era, the increasing
number of discovered therapeutically-relevant factors (11) has
encouraged the development of material systems to fulfill the
requests of delivering these newly identified therapeutic
factors. Readers are referred to excellent reviews for the
application of hydrogels on controlled drug delivery in tissue
engineering and regenerative medicine (2,3,12). In this review,
we will focus on an increasingly useful class of hydrogels
developed in recent years for controlled release and regener-
ative medicine applications. Namely, hydrogels formed from
the polymerization of macromolecular PEG precursors and
the subsequent challenges in the incorporation and release of
biologically important molecules for tissue engineering appli-
cations. Finally, we will also provide a perspective on current
trends in delivery strategies to affect cell survival, proliferation,
and differentiation using these PEG-based materials.
PEG HYDROGEL SYSTEMS
Mechanism of Hydrogel Formation: Step-Growth,
Chain-Growth, or Mixed-Mode Polymerization
While various methods of gelation (i.e., physical, ionic, or
covalent interactions) can be used to form PEG gels,
chemically or covalently-crosslinking leads to relatively stable
hydrogel structures with tunable physicochemical properties
such as permeability, molecular diffusivity, equilibrium water
content, elasticity, modulus, and degradation rate (2,3)
(Fig. 1). Furthermore, the introduction of degradable linkers
into the covalent crosslinks permits the fabrication of well-
defined network structures with tailorable properties in time.
Generally, the synthesis of covalently crosslinked PEG gels
falls into one of the following categories, according to the
crosslinking reaction mechanism (13): chain-growth, step-
growth, or mixed-mode chain and step growth (Fig. 2).
Fig. 2A illustrates the network structure resulting from the
chain-growth polymerization of macromolecular PEG pre-
cursors. Typically, these networks are formed from functional
PEG molecules, such as PEG-di(meth)acrylate (Fig. 3). Poly-
merization is initiated by reactive centers, such as radicals,
generated from thermal energy, redox reactions, or the photo-
cleavage of initiator molecules. These free radicals propagate
through unsaturated vinyl bonds on the PEG macromolecular
monomers and chain polymerization occurs. The propagation
of free radicals through multiple carbon–carbon double bonds
on the constituting PEG monomers results in covalently
crosslinked, high molecular weight kinetic chains. The func-
tionalities of the chain-growth polymerized hydrogels can be
expanded through the copolymerization of other functional
(meth)acrylated macromers. One disadvantage of chain-
growth polymerization, compared to step-growth mechanism,
is that it can lead to lower conversion of the functional groups.
Therefore, when it is used in in situ polymerization, un-reacted
monomers and/or functional groups remaining in the body
may cause local inflammatory reaction or systematic immune
response (14). Furthermore, hydrogels made from chain-
growth polymerization usually contain certain network non-
idealities (15) (Fig. 1A) that may adversely affect drug release
performance and material properties.
Of all the chain polymerization schemes, photopolymeri-
zation is one of the preferable ways to fabricate hydrogels.
Hydrogels formed via photopolymerizations usually take
minutes to complete, and hence, avoid persistent exposure of
biomolecules to thermal energy, a characteristic of thermally
initiated polymerization and a condition generally not suitable
for in situ encapsulation of fragile proteins and cells. The ability
of photopolymerizations to produce stable hydrogel networks
mildly and rapidly provides a convenient and efficient method
for a variety of regenerative medicine applications.
In contrast to the chain growth mechanism, step-growth
gelation occurs when at least two multifunctional monomers
with mutually reactive chemical groups are reacted together
in either stoichiometric balanced or imbalanced ratio, and the
average monomer functionality is greater than 2 (16). Not
only can this conjugation reaction be performed under
ambient conditions without the use of free-radical initiators,
it also produces fewer structural defects during network
formation (17) (Fig. 2B), which permits more precise control
over the gel crosslinking density and subsequent material













Fig. 1. A Simplified crosslinked hydrogel structure. Black dots represent crosslinking point;
ξ represents mesh size of the gel. B Hydrogel property as a function of gel crosslinking
density.
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therapeutics, as it allows accurate mathematical predictions
prior to the delivery, which is highly beneficial for determin-
ing appropriate drug dosing and release kinetics. Hubbell and
colleagues developed a series of degradable hydrogels formed
via step-growth Michael-type addition reaction between
acrylated star PEG polymer and dithiol (18–21). The
degradation products of these gels do not produce high
molecular weight kinetic chains, which may not only exceed
the glomerular filtration limit but may also induce host
inflammatory or immune response. From the standpoint of
protein delivery, Michael-type addition reactions decrease
possible protein damage due to propagating free radicals as
occurred in chain-growth polymerizations, but the presence of
thiol groups may reduce the native disulfide bonds of the
encapsulated proteins and cause protein denaturation, lead-
ing to decreased bioactivity and increased immunogenicity.
Although Michael-type hydrogels have been successfully used
in protein delivery (18–21) and synthetic extracellular matrix
(ECM) for cell in-growth as shown by Hubbell group
(19,22,23), these hydrogels do not permit spatial and tempo-
ral control over the network structure during network
gelation.
Recently, PEG hydrogels formed via “Click” chemistry,
another type of step-growth mechanism, have elicited tremen-
dous amount of interests due to its rapid and specific reaction,
as well as its versatility with respect to bioconjugation. In this
typical reaction scheme, macromers bearing azide and alkyne
functional groups are “clicked” together in the presence of
catalysts (usually copper ions) to form stable covalent linkages
(24,25). The well-defined network structures of click hydrogels
open an avenue for creating hydrogels with excellent mechan-
ical properties, while simultaneously permitting the conjuga-
tion of biomolecules after the hydrogels are crosslinked. In a
recent report by Polizzotti and Anseth (26), spatial and
temporal patterning of click hydrogels was made possible by
a unique two-step fabrication process. PEG hydrogels were
formed via “click” chemistry by reacting tetraazide-function-
alized PEG with diacetylene-functionalized allyl ester poly-
peptide containing photo-reactive acrylate groups in the
backbone of the polypeptide. After gelation, photopolymeri-
zation was utilized to subsequently pattern the click gels with a
polypeptide functionality. This unique hydrogel fabrication
method not only produces PEG hydrogels with exceptional
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Fig. 3. Chemical structures of PEG macromer and its di(meth)acrylate derivatives that
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Fig. 2. Schematic structures of PEGhydrogels formed via:A chain-growth,B step-growth, and
C mixed-mode step and chain growth polymerization. (Components not scale to actual size).
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physical and chemical properties of the PEG hydrogels
independently.
One major drawback for conventional click hydrogels,
however, is that these cycloaddition reactions are usually
catalyzed by copper ion. Due to the cytotoxicity of copper,
conventional click chemistry is not suitable for creating
hydrogel networks with cell encapsulation in situ. Recently,
copper-free click chemistry has been reported by the Bertozzi
group (27,28). The specificity and fidelity of copper-free click
chemistry offers great potential for a variety of regenerative
medicine applications, including live cell imaging, cell surface
engineering, and cell encapsulation.
In addition to chain-growth and step-growth mechanisms,
PEG hydrogel networks can also be formed from mixed-mode
polymerizations that exhibit characteristics between chain and
step-growth polymerizations as shown in Fig. 2C (29–31). This
rapid gelation of mixed-mode polymerization overcomes the
long polymerization time needed in most of the Michael-type
addition reaction. Furthermore, functional macromers, such as
peptides, can be incorporated at lower concentrations (30,31).
Anseth, Bowman and their coworkers have developed a new
type of PEG hydrogels based on the mixed-mode polymeriza-
tion of acrylated monomers and multifunctional thiols (29,32–
35). In this approach, solutions with different molar ratios of
thiol to acrylate groups were prepared, and the polymerization
kinetics were examined either with or without the presence of
initiators (29,32–35). Differing from thiol-acrylate Michael
addition reaction, thiol-acrylate photopolymerization involves
chain transfer of growing polymer chains to thiol monomers
(34). The polymerization rates and acrylate conversion in-
creased in the presence of photoinitiators, as more thiol groups
were added. Unlike chain-growth photopolymerization, the
use of initiator is not required in mixed-mode photopolyme-
rizations; the initiator free mechanism has been studied by
others (33,35). The network structure that results from this
mechanism is directly impacted by the ratio of complimentary
reactive groups. As the ratio of thiol to acrylate groups
increases, the networks transition from being chain-like to
more step-like. In the case of degradable mixed-mode hydro-
gels, the changes in material properties during degradation,
such as swelling, can also be controlled by variations in thiol-
acrylate ratios. This change further permits the control of the
molecular weight distributions of the degradation products,
which is favorable in many regenerative medicine applications
because the degradation products can be naturally eliminated
by renal filtration. Finally, spatial and temporal control is
possible with the mixed-mode photopolymerization reactions.
Hydrogel Properties and Their Importance in Regenerative
Medicine Applications
The essence of using PEG hydrogels to deliver therapeu-
tically-relevant factors for regenerative medicine stems from
its hydrophilicity (3). A loosely crosslinked PEG hydrogel can
easily contain more than 95% of water in its total mass. The
high water-content resembles natural soft tissue and, hence,
creates a suitable environment for many encapsulated bio-
molecules and cells. For tissue regeneration, this is essential as
it offers opportunity for facile nutrient-waste exchange that is
critical for supporting long-term cell/tissue viability. High
water-content, on the other hand, also creates challenges to
the encapsulated cells, as it usually cannot prevent smaller
cytotoxic molecules from passing through the hydrogel barrier.
These cytotoxic molecules, including cytokines and reactive
oxygen species, trigger the cellular apoptotic pathway that
eventually leads to the failure of the encapsulating cells and are
often present at the site of injury/implantation. From the
perspective of controlled release, the high water-content of
PEG hydrogels is critical in maintaining the bioactivity of
hydrophilic biomolecules, but it also creates high permeability
for the encapsulated small molecules (2). Consequently, rapid
release occurs, which not only shortens the efficacy of the
delivery device, but may cause a “dose-dumping” effect that is
potentially harmful for the surrounding tissue.
Another beneficial feature of PEG hydrogels comes
from its “stealth” or anti-fouling property that repels non-
specific protein adsorption and cell adhesion (36,37). This
property is intriguing as it allows for creating functional
patterns either on PEG surfaces or within three-dimensional
PEG hydrogels when modified with proper adhesion mole-
cules. Similar to the high water-content property of PEG
hydrogels, the ability of PEG molecules to prevent non-
specific biomolecular interactions has its pros and cons. For
tissue regeneration, anti-fouling of PEG hydrogels reduces
the adhesion of inflammatory cells onto the hydrogel surface
and decrease the chances of capsule formation. However, this
property also hinders the adsorption of bioactive molecules,
such as extracellular matrix (ECM) proteins that supports the
growth and function of the encapsulated cells. This subse-
quently reduces the viability of encapsulated cells that require
interactions with the surrounding matrix. Fortunately, func-
tional moieties can be easily incorporated within PEG
hydrogels through co-polymerization. A variety of ECM-
derived cell adhesion peptide sequences have been incorpo-
rated within PEG hydrogels to promote the survival of
encapsulated cells, including pancreatic β-cell (38), human
mesenchymal stem cells (18,19,31,39,40), etc.
The applicability of PEG hydrogels in regenerative
medicine can be further augmented by incorporating degrad-
able segments within the PEG hydrogel networks (41). In
particular, the incorporation of hydrolytically degradable poly
(lactic acid) (PLA) groups greatly increase the potential
applications of PEG hydrogels. When PEG hydrogels are to
be used solely as cell delivery scaffolds, the ability to control
their degradation rate is critical for enhancing tissue regener-
ation. For example, tri-block copolymers of PLA-PEG-PLA,
containing polylatic acid (PLA) blocks and acrylate end
groups, have been used to create photo-polymerizable and
hydrolytically degradable hydrogels for controlled release and
regenerative medicine applications (15,42–44). The degrada-
tion rate of the PLA-PEG-PLA hydrogels can be readily pre-
engineered by changing either the polymer content of the
hydrogels or the length of the degradable PLA segments.
Although hydrolytic degradation allows one to pre-
engineer the hydrogel degradation rate, the ability to modify
the gel degradation rate post-fabrication is limited. To over-
come this, Hubbell and colleagues designed Michael-type PEG
hydrogels with MMPs (matrix metalloproteinases) cleavable
linkages to facilitate cell-responsive hydrogel degradation (45)
as well as growth factor release (46). This “cell-dictated”
hydrogel breakdown is highly beneficial for tissue regeneration
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as it eliminates the risks of erroneous/improper engineering
of network degradation and therapeutic liberation profiles.
Rice and Anseth, on the other hand, developed a PEG
hydrogel system incorporating enzyme-labile caprolactone
units for chondrocyte photo-encapsulation (47,48). This unique
enzyme-responsive PEG hydrogel allows one to exogenously
control material degradation through the delivery of a lipase,
and manipulate the gel degradation in response to the
regeneration of tissue.
CONTROLLED RELEASE OF BIOMOLECULES
IN PEG HYDROGELS
Design Criteria for Controlled Release
Many fundamental studies have revealed the structure-
property relationships of PEG-based hydrogels, especially
related to equilibrium swelling, mechanics, and transport
properties (3,7). Stemming from these studies, numerous
PEG-based hydrogel systems have been developed for
controlled delivery of many biomolecules, ranging from small
molecular weight drugs to large biomacromolecules, such as
nucleic acids, peptides, and proteins. Because of the diversity
in the chemistry and size of the delivered molecules, the
design criteria for controlled release in PEG-based hydrogels
can differ widely from one application to another. Neverthe-
less, availability and stability of the therapeutics are two major
concerns when designing PEG hydrogels for controlled
release applications (Table I). To achieve desired therapeutic
efficacy in vivo or in vitro, PEG hydrogels should be capable
of delivering therapeutics at the right dosage (availability)
with preserved molecular bioactivity (stability).
Availability of Biomolecules
The mechanisms by which drugs are released from PEG
hydrogels depend upon multiple factors, including the
method of drug loading, the size and molecular characteristics
of the drug, and the dosage and release profile needed for
specific therapeutic application. In general, the molecular
release mechanisms in PEG hydrogels include diffusion-
controlled, swelling-controlled, and chemically-controlled de-
livery. Readers are advised toward other reviews for detailed
mechanistic descriptions of these release mechanisms (2,3).
When releasing small molecular weight therapeutics such as
synthetic drugs, small peptides and proteins, the high
permeability of PEG hydrogels does not permit facile control
over the release kinetics. One easy way to control molecular
release kinetics is to tune the gel permeability by adjusting
the network crosslinking density. However, this approach
relies on size-exclusion and is not effective when controlling
the release of small molecules. It is also not desirable for most
tissue engineering applications, as a higher crosslinking
density often represents decreased hydrophilicity and hence
decreased cytocompatibility. Therefore, other controlling
mechanisms have to be intelligently implemented if one
wishes to maintain the preferential hydrophilic environments
provided by PEG hydrogels. For example, a variety of
“smart” hydrogels that change their volumetric swelling ratio
in response to external stimuli have been developed for
controlled release applications (3,49–51). Under physiological
stimuli (such as pH, temperature, and ionic strength), these
intelligently designed stimuli-responsive hydrogels can switch
their physical characteristic from a collapsed to swollen state.
In their collapsed state, the encapsulated drugs are protected
from external harmful factors such as proteolytic degradation,
and the encapsulated drugs are subsequently released in the
swollen state under a proper stimulus.
Another strategy for delivering drugs without sacrificing
preferential hydrophilicity of PEG hydrogels is the “pro-
drug” technique. In this approach, therapeutics can be
covalently tethered within PEG hydrogels via pendant
functional groups. The incorporation of degradable linkers
between the tether and the drug allows for pre-determined
liberation and release rates. A variety of linker degradation
mechanisms have been proposed including hydrolytic (52,53)
and enzymatic degradation (54–56). Although the “pro-drug”
technique is an effective means of controlling drug availability
with pre-determined release rates while preserving hydro-
philicity of PEG hydrogels, one drawback of this approach is
that the covalent conjugation of drugs to the degradable
linker may decrease the bioactivity of the drugs, especially
when fragile proteins and peptides are the target therapeutics.
Furthermore, the chemistry of the linker has to be carefully
designed and be biocompatible such that no unwanted host
immune responses will occur due to the remnants of the
partially degraded linker (57,58).
Recently, “affinity” hydrogels have been suggested as an
alternative for controlling drug availability in highly swollen
PEG hydrogels (59–61). By discovering ligands that revers-
ibly bind to target therapeutics and co-polymerizing them
within PEG hydrogels, one can render inert PEG hydrogels
to exhibiting specific affinity toward therapeutics. Other than
facile controlling over drug release in highly permeable
hydrogel environments, the use of affinity hydrogels also
discards the needs of direct chemical modification on fragile
therapeutics such as proteins. A number of affinity mecha-
nisms have been shown to be effective at controlling drug
availability in PEG hydrogels. For instance, cyclodextrin can
be tethered into PEG hydrogels for controlled release of
small molecular weight hydrophobic drugs (62,63). Heparin, a
highly sulfated glycosaminoglycan (GAG), has also been
extensively used to fabricate affinity hydrogels due to its
reversible affinity to a broad variety of growth factors
(59,60,64,65). However, affinity binding through heparin–
protein interactions mainly relies on non-specific electrostatic
interactions. The potential immunogenicity of heparin and
the fact that it binds to numerous proteins further complicate
the release outcome in vivo. Thus, peptide mimetics with
Table I. Design Criteria for Controlled Release in PEG Hydrogels
Design criteria Design variables
Availability of biomolecules Crosslinking density
Molecular weight of polymer
Hydrogel degradation rate
Affinity interaction
Stability of biomolecules Polymer/crosslinker/initiator
concentrations
Stabilizing agents for therapeutics
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specific affinity to target proteins have been explored recently
as an alternative to heparin-based affinity binding (66,67).
Stability of Biomolecules
One challenging task in controlled delivery of biomacro-
molecules is how to maintain their bioactivity during hydrogel
fabrication and throughout the entire course of release.
Maintaining drug stability is of critical importance not only
for therapeutic purposes but also for biocompatibility con-
cerns, as it has been shown that denatured proteins/peptides
can be immunogenic in vivo (68). It is well known that when
encapsulating proteins within hydrophobic polymers (e.g.,
poly(lactide-co-glycolide) or PLGA), protective agents have
to be incorporated within the polymer capsules to reduce
protein denaturation due to acidic degradation products
(lactic acid and glycolic acid) of PLGA (69–71). Similarly,
when proteins or nucleic acids are encapsulated within PEG
hydrogels during radical-based hydrogel crosslinking, the
presence of highly reactive free radicals, as well as undesired
side-reactions between reactive polymer chains and biomole-
cules, can damage the encapsulated biomolecules. Quick and
Anseth have revealed the detrimental effect of free radicals on
encapsulated DNA during in situ photoencapsulation and
demonstrated that the addition of radical scavengers can
effectively preserved the integrity of the encapsulated nucleic
acids (72,73). Proper protein protection strategies (21,74) are
also beneficial for preserving bioactivity of in situ loaded protein
therapeutics. Research from Metters (74,75) as well as from
Amsden et al. (76) revealed that the presence of propagating
carbon free radicals attacks bioactive sites of proteins during in
situ encapsulation. For example, Lin and Metters have shown
that the concentration and characteristic of photoinitiators
greatly affect the bioactivity and availability of hydrogel
encapsulated protein and that the presence of acrylated mono-
mers reinstates protein bioactivity due to the higher reactivity
ratio between free radicals and acrylate bonds (74,75).
Loading and Release Mechanisms in PEG Hydrogels
The means by which the drugs are loaded directly impact
the availability of the drugs during release. For example,
drugs can be loaded into hydrogels through entrapment
(Fig. 4A). Since hydrogels are highly swollen polymer
networks, drugs can be dispersed uniformly within hydrogel
matrices through either post-fabrication equilibrium parti-
tioning (drugs are loaded through incubating gels in concen-
trated drug solutions) or in situ encapsulation (drugs are
encapsulated during network crosslinking). While the former
method ensures preserved drug stability (no potential chem-
ical reactions between drugs and hydrogel network during
crosslinking/polymerization processes), it does not permit
accurate control over the amount of drug loading due to
partition limitations. Furthermore, it is difficult to prepare
hydrogels loaded with multiple drugs at controllable levels for
sophisticating regenerative medicine applications where co-
operative/synergistic actions of multiple factors are usually
required. On the other hand, in situ encapsulation, a process in
which drug loading and hydrogel network crosslinking are




Proteases (enzymatic degradation) 
or water (hydrolytic degradation)
(A) (B)
Therapeutics-loaded microparticle
Fig. 4. Schematic of methods for loading of therapeutics into PEG hydrogels: A
entrapment: Drugs are loaded into hydrogels via in situ entrapment or post-fabrication
equilibrium partitioning. B Tethering: Drugs are modified with a crosslinkable and
cleavable linker that can be liberated once the tethers are degraded hydrolytically or
enzymatically. C Multiphase loading: Drugs are pre-loaded into microparticles that are
subsequently entrapped in hydrogels. (Components not scale to actual size).
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loaded with multiple, high quantity drugs in a rapid and mild
manner. More importantly, it can also be used to simultaneously
encapsulate cells under mild physiological conditions for
regenerative medicine applications. The disadvantage of in situ
loading, however, is that the polymerization reactions can
potentially induce undesired reactions on fragile biomolecules
or between the encapsulated molecules and polymer network
(see previous section). Peppas and coworkers developed a series
of pH-sensitive poly(methacrylic acid)-grafted-ethylene glycol
(poly(MAA-g-EG)) hydrogel microparticles for oral insulin
delivery (7,77–84). The interaction between pendant metha-
crylic acid and the grafted ethylene glycol chains provides the
pH-responsiveness of the hydrogels. At low pH (stomach)
environment, these gels collapse due to the protonation of
pendant MAA groups inducing hydrogen bonding with the
oxygen on PEG chains. At higher pH environments, such as in
the small intestines, this hydrogen bonding is disrupted because
of the deprotonation of MAA groups. As a result, the gels swell
and permit diffusion of insulin. The physical encapsulation of
insulin limits proteolytic degradation of insulin before it reaches
the targeted delivery site, preferentially the colon. In addition,
the carboxylic acids tethered on the polymer chains chelate
metal ions that are essential for enzymatic functions, thus further
increasing the bioavailability of the encapsulated insulin. Poly
(MAA-g-EG) hydrogels also exhibit mucoadhesiveness (83),
which enhances the adsorption of hydrogel microparticles and
promotes the utilization of encapsulated insulin. Two factors
contribute to this mucoadhesiveness. First, carboxylic acids on
poly(MAA) interact with the glycoprotein component of the
mucus membrane. Second, the pendant MAA and PEG chains
interpenetrate into the mucin layer. The use of poly(MAA-g-
EG) microparticles represents a substantial success for orally
delivering insulin. In a recent report focusing on oral adminis-
tration of insulin, hypoglycemic effects were observed for both
type 1 and type 2 diabetic rats (84).
In addition to entrapment, drugs can also be incorporated
within PEG hydrogels through tethering (Fig. 4B). Hubbell
and coworkers have tethered growth factors within PEG-
based hydrogels through enzyme-sensitive peptide linkers. In
this approach, therapeutic proteins such as vascular endothe-
lial growth factor (VEGF) can be covalently immobilized
within hydrogel networks by enzyme-sensitive oligopeptides
(54–56). The release of VEGF is mediated by proteases (e.g.,
matrix metalloproteinases or MMPs) secreted by migrating
cells. The cell-demanded VEGF release matches the release
profiles with cellular activity that is critical during tissue
regeneration. These enzymatically degradable gels can be
formed by photopolymerization or Michael-type addition
reaction. The gel characteristics, such as gel formation and
swelling, are shown to be unaffected by the incorporation of
bulky oligopeptides. Integrin-binding domain (RGD) can also
be incorporated into the synthetic biomimetic hydrogel
matrices, as pendant chains to facilitate cell adhesion (54).
These peptide-containing PEG hydrogel systems can be de-
graded by proteolytic enzymes secreted by migrating cells, such
as collagenase, plasmin, and MMPs. The degradation of the
peptide substrate is only sensitive to the corresponding protease.
For example, the degradation of the peptide substrate Pro-Leu-
Gly-Leu-Trp-Ala-D-Arg is sensitive to MMP-1 and MMP-9
(85). The main advantage of these approaches is that the
cellularly controlled gel-degradation rate self-adjusts to the rate
of cell infiltration, as gel degradation only occurs when specific
enzymes are secreted by migrating cells. The cell-mediated gel
degradation as well as growth factor release makes these gels
extremely attractive for tissue regeneration applications, as
these biomimetic materials only serve as provisional matrices
and are degraded by invading cells.
Finally, therapeutics can also be loaded into hydrogels
through the incorporation of micro or nanoparticles (Fig. 4C).
The presence of multiphases (bulk hydrogel and dispersed
microparticles) facilitates the incorporation and delivery of
multiple therapeutics. For example, Mikos and colleagues have
synthesized such composite hydrogel devices for dual growth
factor delivery (86,87). Two growth factors, insulin-like growth
factor 1 (IGF-1) and transforming growth factor-β (TGF-β),
were incorporated separately within bulk hydrogels made of
poly(propylene fumarate-co-ethylene glycol) (P(PF-co-EG))
or oligo(poly(ethylene glycol) fumarate (OPF) and gelatin
microparticles embedded within bulk hydrogels (87). The
delivery rates of the two growth factors were independently
tuned by adjusting the loading positions or hydrogel cross-
linking density. These hydrogels are biodegradable, injectable,
in situ photocrosslinkable, and biocompatible. The degrada-
tion of these hydrogels occurs at the ester linkage within the
poly(propylene fumarate) block and can be accelerated by
decreasing pH and/or crosslinking density. Because of their
excellent structural properties as well as the capability of
independently controlling the delivery of multiple factors,
these hydrogels hold great potential in drug delivery for
regenerative medicine applications.
PEG HYDROGELS IN EMERGING REGENERATIVE
MEDICINE
Spatiotemporal-Controlled Delivery for Controlling Cell Fate
Advances in drug delivery technologies for tissue regen-
eration have emerged from delivering single therapeutics for
tissue regeneration (88,89) to temporal regulation of two
factors to promote vascularization (90) to increasingly sophis-
ticated strategies to present survival or differentiation cues for
stem/progenitor cell differentiation (91–93). While much effort
has been dedicated to identifying which biochemical cues are
most critical and fabricating appropriate material delivery
systems, opportunities and challenges exist for developing
advanced drug delivery strategies to accelerate differentiation
processes toward committed pathways. Currently, the delivery
of survival or differentiation cues for controlling cell fate
(either 2D or 3D culture) is usually through medium supple-
ments (i.e., adding growth factors in cell culture medium).
Although simple, this approach does not mimic the complex in
vivo environments where the biochemical cues for tissue
development and/or repair are usually presented in temporally
and spatially-regulated manner. For tissue regeneration pro-
cesses that require sequential presentation of multiple growth
factors, PEG hydrogel matrices must be designed in a way that
the delivery rates of multiple biochemical cues match the needs
of neo-tissue development. Intelligent hydrogel matrices, such
as the aforementioned multiphase composites and affinity
hydrogels, should provide one such approach for temporally-
controlled delivery of multiple factors.
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Increasingly, the recruitment of multiple cell types such
as inflammatory, immune cells and tissue-specific progenitor
cells is acknowledged as important for the tissue regeneration
process (94). A typical example is peripheral nerve regener-
ation where nerve cells migrate/proliferate toward increasing
concentrations of neurotrophic factors. Although the exact
mechanisms by which multiple cell types are attracted
sequentially to the site of injury and the congruous interplay
between these cell types are currently under intensive
investigation, it is generally recognized that chemotaxis plays
an important role in dictating cell migration (94). Therefore,
it would be beneficial to create chemical gradients in
biomaterials for facilitating migration and proliferation of
host cells into the biomaterial environments. Toward this end,
initial efforts on surface chemistry and engineering have lead
to substantial success and numerous surface patterning and
grafting techniques have been developed to generate chem-
ical gradients for guiding cell migration (95–97). On the other
hand, the creation of spatially-regulated biochemical cues
presentation in 3D hydrogels faces more challenges. One way
of circumventing 3D hydrogel patterning is through the use of
single- or two-photon confocal laser scanning microscopy
(CLSM). Due to the spatial precision of laser-guided
patterning and the elimination/suppression of out-of-focus
light, precise 3D patterning can be created within a 3D
hydrogel structure. Taking advantage of CLSM, Luo and
Shoichet have developed photolabile agarose hydrogel for
spatially patterning RGD peptide for cell adhesion and
migration (98). In this approach, a photolabile 2-nitrobenzyl
group was used to protect thiol groups. Upon laser-guided
UV exposure, the 2-nitrobenzyl groups were cleaved, leaving
free thiol exposed. Maleimide-modified biomolecules were
then spatially conjugated within the hydrogels through the
thiol-maleimide reaction. Neuron cell migration and neurite
outgrowth were observed only within patterned RGD chan-
nels. The use of CLSM to create spatially patterned chemical
cues should prove useful in the design and fabrication of PEG
hydrogels. In an alternative approach, West et al. have
developed PEG hydrogels patterned with biochemical gra-
dients that promote cell adhesion and migration (99–101).
The patterns were created by forming partially crosslinked
PEG hydrogels, followed by diffusing acrylated bioactive cues
within the hydrogels. CLSM was subsequently used to photo-
crosslink bioactive cues within PEG hydrogels. Using this
simple approach, complex 3D geometries can be patterned
within PEG hydrogels.
Recent advances in “click” chemistry also open avenues
for spatially patterning biomolecules within PEG hydrogels.
As mentioned in the previous section, a patterning scheme
combining click chemistry and photopolymerization adopted
by Polizzotti and Anseth offers novel approaches of creating
spatially regulated biochemical cues presentation (26). This
method should provide greater therapeutic applicability when
copper-free click chemistry is incorporated.
Although laser-guided photopatterning techniques have
proven effective in generating 3D hydrogels with spatially
immobilized biochemical cues, one question remains to be
answered. Can this technique be used to create hydrogel
matrices loaded with spatially-distributed growth factors that
are only needed temporally? Lessons from wound healing
and organ/tissue development have revealed the importance
of spatiotemporal distribution of biochemical cues. For
example, recent studies have suggested that the persistent
presence of the integrin-binding peptide motif Arg-Gly-Asp
(RGD) hinders complete chondrogenic differentiation of
human mesenchymal stem cells (hMSCs) within hydrogels
(31,102,103). On the other hand, Salinas and Anseth designed
PEG hydrogels immobilized with MMP-13 cleavable RGD
motif for enhancing chondrogenesis of hMSCs (31). A ten-
fold increased in glycosaminoglycans (GAGs) production
(indication of chondrogenic differentiation) by encapsulated
hMSCs was obtained when the linker to RGD motif was
cleaved by MMP-13. Therefore, to design the next generation
of bioactive hydrogels, new techniques capable of selectively
removing biochemical cues should greatly facilitate stem cell
differentiation and tissue regeneration.
Hybrid Hydrogels for Dynamic Sensing, Actuation,
and Controlled Release
Stimuli-sensitive polymers have been successfully used to
fabricate “smart” hydrogels for controlled release applica-
tions, including the pH-responsive gel systems for oral insulin
delivery developed by Peppas et al. (78,80,84). More recently,
hybrid hydrogels composed of synthetic polymers and bio-
logical components, such as proteins and peptides, are
subjects of intense research (104,105). Differing from con-
ventional stimuli-responsive synthetic polymers/hydrogels
where the responsiveness usually comes from changes in
physical parameters (e.g., temperature, pH, or hydro-
phobicity), the responsiveness of hybrid hydrogels is a result
of biological recognitions or protein–ligand interactions.
Typically, proteins with the ability to change their conforma-
tions upon ligand binding are first modified (either chemically
or genetically) with crosslinkable moieties, followed by
conjugating with synthetic polymer chains to form hybrid
hydrogels. The uniqueness of this type of stimuli-responsive
hydrogels is their ability to transform biological recognition
events (protein–ligand binding) into mechanical displace-
ments (hydrogel swelling).
Since the conception of hybrid hydrogels in the late
1990s by Kopecek et al. (104,105), several examples of such
responsive systems have been proposed. For example,
Daunert and co-workers designed acrylamide-based hydrogel
containing genetically engineered protein–calmodulin (CaM)
(106,107). The molecular recognition between CaM and
calcium ions triggers the conformational change of CaM and
its binding to phenothiazine (both CaM and phenothiazine
were polymer-conjugated). This calcium-dependent binding
subsequently results in reversible hydrogel swelling changes.
Murphy et al. went on to develop PEG-based hybrid hydro-
gels that incorporate CaM molecules (108,109). The concept
of biological-synthetic hybrid hydrogels opens avenues for the
design and fabrication of stimuli-responsive microfluidic
devices, biosensors, actuators, and miniaturized drug delivery
systems.
In addition to the protein–ligand binding, another type of
hybrid hydrogels developed for controlled release applica-
tions is based on protein-receptor binding. Kiick et al.
developed receptor-responsive hydrogels assembled by
heparin-binding growth factors and heparin-functionalized
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star PEG polymers for the delivery of vascular endothelial
growth factor (VEGF) (110,111) and basic fibroblast growth
factor (bFGF) (112). In this novel responsive hydrogel system,
growth factors are not only therapeutics but also act as
crosslinkers for hydrogel assembly. The receptor-responsive
hybrid hydrogels are self-assembled via reversible binding
between VEGF (or bFGF) and heparin conjugated on star
PEG polymers. Upon reaching cell surfaces, the growth factors
are removed due to binding to receptors. This causes the
hydrogels to disassemble due to the loss of crosslinkers.
Although this approach is intelligent and has been proven to
be effective on promoting cell proliferation in vitro, the non-
specific binding between heparin and a variety of growth
factors makes it challenging to deliver growth factors in vivo as
the heparin-bound growth factors may be replaced by other
growth factors (or other biomolecules) exhibiting stronger
affinity for heparin before the delivery vehicles reach the
target site. The specificity and fidelity of this approach,
however, can be expanded when affinity peptides with specific
affinity for growth factors are discovered for binding and
hybrid hydrogel assembly.
PEG Hydrogels for Controlled Stem Cell Differentiation
As briefly mentioned earlier in this section, PEG hydro-
gels have been shown to be useful in studying stem cell
differentiation in 3-D environments. This is mainly due to the
“blank slate” or “inert” PEG networks that make it possible
to identify the effects of specific bioactive molecules on the
encapsulated stem cell fate (113). For example, Anseth
(31,40,53,91,113–118), Elisseeff (103,119–122) and their col-
leagues have extensively studied the effect of PEG hydrogel
environments on controlling the osteogenic or chondrogenic
differentiation of human mesenchymal stem cells (hMSCs) or
embryonic stem cells (ESCs). To promote the survival of
anchorage-dependent hMSCs or ESCs, cell-adhesion mole-
cules, such as RGD peptide, were co-polymerized within
PEG-based hydrogels (103,118). Furthermore, it has been
shown that the incorporation of bioactive molecules within
PEG-based hydrogels have a significant impact on the
differentiation of hMSCs. For example, heparin (53,91) or
phosphate (115,122) functionalized PEG hydrogels have been
shown to promote osteogenic differentiation of hMSCs in the
gel environments, possibly due to the retention of cell-secreted
bioactive molecules within the functionalized hydrogels. With
proper design and selection of functional groups, PEG hydro-
gels can also be used to induce chondrogenic (31,40,103,118)
and adipogenic differentiation (123,124) from hMSCs.
Controlled stem cell differentiation can also be achieved
by retaining cell-secreted biomolecules within PEG hydro-
gels. In in vivo environments, cells usually reside within dense
extracellular matrix environments that can effectively retain
cell-secreted bioactive molecules for autocrine signaling or
other feedback mechanisms. The major benefits of retaining
cell-secreted biomolecules, rather than covalently incorporat-
ing their synthetic or recombinant analogs within gel environ-
ments, are two fold. First, these molecules may only be
needed temporarily during the differentiation processes.
Secondly, the bioactivity of cell-secreted biomolecules may
be more potent than synthetic or recombinant analogs.
Although crosslinked hydrogel networks can effectively
retain large, cell-secreted large ECM molecules due to the
size-exclusion effect, small growth factors and other bioactive
molecules secreted by the encapsulated cells may easily
diffuse out of the crosslinked gels. As discussed in the
previous sections, simply increasing gel crosslinking density
is not an effective way of retaining small bioactive molecules
within the highly permeable hydrogel environment. There-
fore, identify affinity binding motif for specific biomolecules
and covalently incorporate them within PEG hydrogels may
greatly promote the survival, function, and differentiation of
the encapsulated cells. The incorporation of peptide sequence
KLER, a collagen II binding domain derived from decorin,
has been shown to promote chondrogenic differentiation of
hMSCs in PEG hydrogels (117). Although the binding
between heparin and growth factors is not considered
specific, the incorporation of heparin within PEG hydrogels
can also be used as a binding mechanism for retaining cell-
secreted growth factors (53).
CONCLUSION
With growing research interest in the use of PEG
hydrogels for regenerative medicine applications, proper
delivery strategies should be impregnated within PEG hydro-
gels to fulfill the diverse nature of tissue development/
regeneration, as this will significantly affect the outcome of
tissue regeneration. For delivering therapeutics to repair
damage tissues, methods for tailoring availability and stability
of bioactive molecules should be considered in parallel to
augment the regeneration processes. For delivering survival
and differentiation cues, general considerations should incorpo-
rate critical aspects of the dynamic in vivo environments and
lessons from organ/tissue developments should provide valuable
information regarding the criteria of hydrogel design. The
development of in situ forming PEG hydrogel chemistry and
fabrication techniques have offered a solid foundation on which
current and future delivery strategies are built.
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